Skip to main content

Salvage Treatment for Recurrent Oral Cancer

  • Chapter
  • First Online:
Contemporary Oral Oncology

Abstract

The surgical treatment of recurrent or previously treated malignancies of the oral cavity presents one of the greatest challenges known to the head and neck surgeon and reconstructive oncologist. These problems are faced with unfortunate frequency and bring oft-devastating functional cost along with the very real threat of death from uncontrolled locoregional disease. The “successful” (long-term locoregional control, effective palliation, the occasional cure) treatment of these cases requires technical expertise and judgment known only to the most experienced head and neck surgeon. Despite this, treatment failure is common and humbling.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Similar content being viewed by others

References

  1. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562.

    Article  CAS  Google Scholar 

  2. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864.

    Article  CAS  Google Scholar 

  3. Machiels J, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–94.

    Article  CAS  Google Scholar 

  4. Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015;33(Suppl; abstr LBA6008).

    Google Scholar 

  5. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116.

    Article  CAS  Google Scholar 

  6. Pajwani L. Nivloumab may be “game-changer” in head & neck cancer. Onc Live. 2016;17(5):33, 03.16.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark D. DeLacure MD, FACS .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

DeLacure, M.D., Sanfilippo, N.J. (2017). Salvage Treatment for Recurrent Oral Cancer. In: Kuriakose, M. (eds) Contemporary Oral Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-14917-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14917-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14916-5

  • Online ISBN: 978-3-319-14917-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics